Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy

Lung Cancer

Volumn 65, Issue 1, 2009, Pages 98-104

  Leithner, Katharina ^a   Stacher, Elvira ^a   Wurm, Robert ^a   Ploner, Ferdinand ^a   Quehenberger, Franz ^a   Wohlkoenig, Christoph ^a   Bálint, Zoltán ^a   Polachova, Jana ^a   Olschewski, Andrea ^a   Samonigg, Hellmut ^a   Popper, Helmut H ^a   Olschewski, Horst ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Apoptosis; DR5; Non small cell lung cancer; Nuclear; Prognosis

Indexed keywords

CELL NUCLEUS RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; PLATINUM; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ASSESSMENT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SUBCELLULAR FRACTIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 67249100235     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.10.015     Document Type: Article

References (33)

1. Manegold C., and Thatcher N. Survival improvement in thoracic cancer: progress from the last decade and beyond. Lung Cancer 57 Suppl 2 (2007) S3-S5
2. Socinski M.A. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res 10 (2004) 4210s-4214s
3. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
4. Jin Z., and El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol Ther 4 (2005) 139-163
5. Wang S., and El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22 (2003) 8628-8633
6. Duiker E.W., Mom C.H., de Jong S., Willemse P.H., Gietema J.A., van der Zee A.G., et al. The clinical trail of TRAIL. Eur J Cancer 42 (2006) 2233-2240
7. de Vries E.G., Gietema J.A., and de Jong S. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res 12 (2006) 2390-2393
8. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61 (2008) 82-90
9. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
10. Zhang X.D., Franco A.V., Nguyen T., Gray C.P., and Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 164 (2000) 3961-3970
11. Zhang X.D., Franco A., Myers K., Gray C., Nguyen T., and Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59 (1999) 2747-2753
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
13. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
14. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122 (2002) 1037-1057
15. Lancaster J.M., Sayer R., Blanchette C., Calingaert B., Whitaker R., Schildkraut J., et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 9 (2003) 762-766
16. Zhuang L., Lee C.S., Scolyer R.A., McCarthy S.W., Zhang X.D., Thompson J.F., et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 37 (2006) 1286-1294
17. McCarthy M.M., Sznol M., DiVito K.A., Camp R.L., Rimm D.L., and Kluger H.M. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11 (2005) 5188-5194
18. Strater J., Hinz U., Walczak H., Mechtersheimer G., Koretz K., Herfarth C., et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8 (2002) 3734-3740
19. van Geelen C.M., Westra J.L., de Vries E.G., Boersma-van Ek W., Zwart N., Hollema H., et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 24 (2006) 4998-5004
20. Han J.Y., Hong E.K., Choi B.G., Park J.N., Kim K.W., Kang J.H., et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol 20 (2003) 355-362
21. Spierings D.C., de Vries E.G., Timens W., Groen H.J., Boezen H.M., and de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9 (2003) 3397-3405
22. Zerafa N., Westwood J.A., Cretney E., Mitchell S., Waring P., Iezzi M., et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 175 (2005) 5586-5590
23. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., and Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168 (2002) 1356-1361
24. Wang S., and El-Deiry W.S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64 (2004) 6666-6672
25. Shivapurkar N., Toyooka S., Toyooka K.O., Reddy J., Miyajima K., Suzuki M., et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109 (2004) 786-792
26. van Noesel M.M., van Bezouw S., Salomons G.S., Voute P.A., Pieters R., Baylin S.B., et al. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62 (2002) 2157-2161
27. Shivapurkar N., Stastny V., Suzuki M., Wistuba I.I., Li L., Zheng Y., et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247 (2007) 56-71
28. Lin-Lee Y.C., Pham L.V., Tamayo A.T., Fu L., Zhou H.J., Yoshimura L.C., et al. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem 281 (2006) 18878-18887
29. Ferrando-May E. Nucleocytoplasmic transport in apoptosis. Cell Death Differ 12 (2005) 1263-1276
30. Macara I.G. Transport into and out of the nucleus. Microbiol Mol Biol Rev 65 (2001) 570-594
31. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3 (2001) 802-808
32. Lo H.W., Hsu S.C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7 (2005) 575-589
33. Zhou H.J., Pham L.V., Tamayo A.T., Lin-Lee Y.C., Fu L., Yoshimura L.C., et al. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood 110 (2007) 2121-2127